OASIS-4 Trial

Learn with

, the lead investigator of the OASIS-4 trial, who provides an overview of the study findings and their potential clinical implications.

Explore this 8 min recorded webinar.

can significantly affect the quality of life for women with breast cancer receiving adjuvant endocrine therapy, yet treatment options remain limited. 

Data from the

,

highlighting the efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy, were delivered as an oral presentation at ASCO 2025 and are now published.

 

Key Takeaways:

• OASIS-4 is a pivotal randomised, placebo-controlled, Phase III trial assessing elinzanetant for the treatment of vasomotor symptoms associated with endocrine therapy among women with or at high risk for HR-positive breast cancer.

• Compared to placebo, elinzanetant resulted in significant improvements in the primary endpoint of VMS frequency, as well as key secondary endpoints of sleep disturbances and menopause-related quality of life.

• Elinzanetant had a safety and tolerability profile that was similar to placebo in this patient population.

 

In this video, Fatima Cardoso, the lead investigator, provides an overview of the study findings and their potential clinical implications.

_{This information is intended for healthcare professionals only.} 

_{The publication of this content was sponsored by Bayer Consumer Care AG}